University of Leicester
Eligibility of patients with type 2 diabetes for sodium-glucose cotransporter 2 inhibitor cardiovascular outcomes trials A global perspective from the DISCOVER study.pdf (850.4 kB)

Eligibility of patients with type 2 diabetes for sodium-glucose cotransporter 2 inhibitor cardiovascular outcomes trials: A global perspective from the DISCOVER study

Download (850.4 kB)
journal contribution
posted on 2019-06-24, 10:38 authored by S Pintat, P Fenici, N Hammar, L Ji, K Khunti, J Medina, F Tang, E Wittbrodt, F Surmont
Objective To assess the eligibility of patients participating in DISCOVER (a 3-year, prospective, observational study program of 15 992 patients with type 2 diabetes [T2D] initiating a second-line glucose-lowering therapy across 38 countries) for four cardiovascular outcomes trials (CVOTs) of sodium-glucose cotransporter 2 inhibitors (CANagliflozin cardioVascular Assessment Study [CANVAS], Dapagliflozin effect on CardiovascuLAR Events trial [DECLARE-TIMI 58], EMPAgliflozin cardiovascular OUTCOME event trial [EMPA-REG OUTCOME], and eValuation of ERTugliflozin effIcacy and Safety CardioVascular outcomes trial [VERTIS-CV]). Research design and methods In this cross-sectional analysis, baseline characteristics of DISCOVER patients were compared with the inclusion and exclusion criteria of the CVOTs to assess patient eligibility, overall and in four regions (Asia-Pacific, Europe, Latin America, and Middle East and Africa). Results Overall, 11 385 patients (71.2%) had sufficient data for the analysis; 56.1% were men. The mean age and time since T2D diagnosis were 57.4 and 5.6 years, respectively. The mean glycated hemoglobin level was 8.3%. DISCOVER patients were younger, and fewer had a history of cardiovascular disease, than those enrolled in the CVOTs. Eligibility varied across the CVOTs; the proportion of eligible DISCOVER patients was highest for DECLARE-TIMI 58 (40.5%), followed by CANVAS (19.9%), VERTIS-CV (7.2%), and EMPA-REG OUTCOME (7.1%); 54.6% of patients were not eligible for any CVOT. Eligibility for each CVOT varied across regions, which was explained by the differing proportions of patients with established cardiovascular disease. Conclusions In a large, international population of patients with T2D initiating a second-line glucose-lowering therapy, DECLARE-TIMI 58 was the most inclusive CVOT, suggesting that its study population will be more representative of patients encountered in routine clinical practice than those of CANVAS, EMPA-REG OUTCOME, and VERTIS-CV.


The DISCOVER and DECLARE‑TIMI 58 studies are funded by AstraZeneca. The CANVAS study is funded by Janssen. The EMPA-REG OUTCOME study is funded by Boehringer Ingelheim and Eli Lilly. The VERTIS-CV study is funded by Merck Sharp & Dohme and Pfizer.



BMJ Open Diabetes Research and Care, 2019;7:e000627

Author affiliation

/Organisation/COLLEGE OF LIFE SCIENCES/School of Medicine/Diabetes Research Centre


  • VoR (Version of Record)

Published in

BMJ Open Diabetes Research and Care


BMJ Publishing Group



Acceptance date


Copyright date


Available date


Publisher version


DISCOVER data underlying the findings described in this manuscript may be obtained in accordance with AstraZeneca’s data sharing policy described at



Usage metrics

    University of Leicester Publications


    No categories selected



    Ref. manager